# AstraZeneca Allemansfond

The fund is actively managed special fund (non-UCITS) and thereby the fund deviates from a UCITS fund by concentrating holdings to a smaller number of equities issued by companies in primarily Sweden. The fund invests a significant amount (maximum of 50% of assets) in AstraZeneca. For this fund, the fund company's Enhanced exclusion level applies. For information about sectors that the fund excludes, see the Detailed information tab. The fund is reported as an Article 8 fund pursuant to EU regulation 2019/2088 on sustainability-related disclosures in the financial services sector (SFDR).

## **Performance**

21.11.2024


YTD	1 week	1 mth.	3 mån	1 year	5 years	10 years
7.15%	-2.82%	-8.31%	-9.55%	14.03%	84.65%	241.25%

## Average performance

Average. perf.	2 years	3 years	5 years	10 years
Fund <sup>1</sup>	16.26%	10.43%	14.03%	14.02%
Index <sup>2</sup>	15.64%	8.25%	-	-

<sup>&</sup>lt;sup>1</sup> Calculated on the fund's monthly closing price

## Five years performance



### **Portfolio**



### Portfolio manager comments — Q3 2024

Fund performance was largely unchanged during Q3. The holdings with the strongest contribution to returns included Assa Abloy, which has posted strength in the wake of a more positive sentiment related to the construction sector following the announcement of lower interest rates, as well as Essity, following the strong results reported for Q2 with higher than expected margins. AstraZeneca also contributed positively after positive study results and a favorable climate for defensive companies overall. Hexagon had the most negative impact on fund returns after reporting weaker than expected results due to exposure to the automotive sector. Autoliv also posted weakness on the back of the same theme and has also had to struggle with its product mix. SEB also had a negative impact due to lower interest rates. During the quarter the fund increased the holdings in Thule, Sampo, Volvo AB and in banks. The fund also sold the holding in Lifco due to a

## **Fund manager**



#### **Ulrika Orstadius**

Experience in the fund industry 2011. Portfolio Manager since 1 November 2022.

Main Calegory	Equity I und
Risk	4
Rate	3777.05 (21.11.2024
Reporting Currency	SEK
Price/Trade	Daily

Price/Trade Daily

Total Rating™ \*\*\*\*

Minimum investment 0 SEK

Minimum investment 0 SEK
Monthly savings 0 SEK
Traded on the Internet No
Management Fee 0.9%
Entry charge 0%
Exit charge 0%

Fund assets 4,737 MSEK
Distribution per fund -

unit
Distribution date -

Fund, date of launch 01.04.1984 Share class, date of 01.04.1984

launch

## **Largest holdings**

AstraZeneca PLC	42.72%
Volvo AB Class B	5.99%
Assa Abloy AB Class B	5.01%
Skandinaviska Enskilda Banken AB Class A	4.50%
Hexagon AB Class B	4.19%
Essity AB Class B	3.61%
Sandvik AB	3.21%
Beijer Ref AB Class B	3.08%
ABB Ltd	3.02%
Svenska Handelsbanken AB Class A	2.97%

<sup>&</sup>lt;sup>2</sup> Benchmark index: SIX SRI Sweden Index GI (60%), AstraZeneca (40%). The information in the table refers to the benchmark index valid at any given time. In the event the fund has previously had other benchmark indexes, this information can be found in the fund's annual report.

high valuation, together with cyclical exposure. We also decreased the holding in Autoliv as a result of the current uncertainty prevailing within the automotive industry.

In the upcoming reporting period we will continue to focus on investee companies that have sustainable business models and competitive offers with sustainable growth even in a weaker economy.

As of: 16.10.2024

Historical yields are not a guarantee of future returns. A fund can both increase and decrease in value and it is not guaranteed that you will recover the entire invested amount. Note that a fund with risk level 5-7, as stated in the fund's fact sheet (KID), can vary greatly in value due to the fund's composition and management methodology. The prospectus, fund rules and KID are available under each fund. <a href="Summary of investors">Summary of investors</a>' rights.

The fund's fact sheet, risk level, fund rules and prospectus are available at www.handelsbanken.se/funds. Handelsbanken does not assume liability for any errors in the information.

www.handelsbanken.se/funds

Handelsbanken